FDA's elevated meeting status signals transition from biomarker data discussions to Accelerated Approval discussions OS ...
Drug delivery researchers have vastly improved the potential of genetic therapies by overcoming the challenge of consistently getting genes and gene-editing tools where they need to be within cells.